Article
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
18 May 2021
Abstract excerpt
The recognition of homologous recombination deficiency (HRD) as a frequent feature of high-grade serous ovarian cancer (HGSOC) has transformed treatment paradigms. Poly(ADP-ribose) polymerase inhibitors (PARPis), developed based on the rationale of synthetic lethality that predicates antitumor efficacy in tumors harboring underlying HRD, now represents an important class of therapy for HGSOC. Recent data have...
Topics
Join the communities discussing this publication.